Introduction: The Wrong Question About Reinfection
Every time a new COVID variant emerges, the public health conversation follows the same script. Is it more severe? How many mutations does it have? Will the current vaccine protect against it (hah!)? Are hospitalizations rising?
For people with Long COVID, Post-Vaccine Syndrome, or any history of spike protein-related illness, they are almost entirely the wrong questions.
The correct question isn’t whether the COVID, or the latest variant Cicada variant (BA.3.2), causes more severe acute illness than previous strains. The correct question is: what does each additional COVID exposure do to someone who already has persistent spike protein, ongoing cellular senescence, and an immune system that never fully resolved the first round?
The answer, supported by emerging research from scientists at the Vedicinals group and consistent with what we observe clinically, is deeply concerning. It is also largely absent from mainstream COVID coverage.
This post explains why reinfection matters in a way that the standard messaging doesn’t capture, what the Cicada variant means specifically for this patient population, and what can be done to reduce the biological cost of repeated exposure.
What the Cicada Variant Actually Is
As of early April 2026, BA.3.2 has been detected in more than half of US states, according to the CDC. The WHO classified BA.3.2 as a variant under monitoring in December 2025, citing the variant’s many mutations and substantial antibody escape.
What makes Cicada notable is not its acute severity, but its spike protein. Compared to the current predominant strains of SARS-CoV-2, BA.3.2 carries 70 to 75 genetic changes in its spike protein. Of course, we alredy know the spike protein drives fibrinogen misfolding, mast cell activation, endothelial dysfunction, microclotting, and cellular senescence in Long COVID patients. But, Cicada’s mutations may help it evade antibodies. In a patient population where immune dysfunction is already significant, this is something Long COVID and Post-Vaccine Syndrome patients need to take note of for reasons explained later in this post.
Importantly, early data suggests BA.3.2 does not cause more severe acute disease than recent variants.
For the general public, that assessment is probably reassuring. For patients with existing spike protein burden and senescent cell accumulation, it misses the point entirely.
The Framework That Changes Everything: Spike Persistence and the Senescence Cascade
To understand why reinfection matters so much for this patient population, you need to understand a mechanistic framework that is only now beginning to enter the scientific literature, and that we at Leading Edge Clinic have been treating clinically.
A recently published paper from researchers at the Vedicinals group and collaborating institutions advances a hypothesis that brings together two phenomena that have been observed separately but rarely connected with sufficient clinical clarity – persistent spike protein production and progressive cellular senescence.
The key insight is this: Long COVID may not be primarily a problem of “how much spike is left over” from an infection. It may be a problem of ongoing spike production from a small population of cells that never stopped making it.
The Persistent Producer Cell
The paper proposes that a small number of cells, potentially harboring viral RNA in protected intracellular compartments called double-membrane vesicles, or having integrated spike-encoding genetic material, continue to produce and release spike protein long after the acute infection resolves. These “producer cells” generate modest amounts of spike individually, but their output is continuous, and it accumulates in tissues over time.
This would explain a striking observation from a high-volume European Long COVID diagnostic laboratory: spike protein detectability in Long COVID patients rose from roughly 30–40% in 2024, to approximately 75% in the first three quarters of 2025, to 96.5% by the fourth quarter of 2025. Under a simple “leftover antigen slowly clearing” model, you would expect a declining curve. A rising curve points toward ongoing production – an active source term, not residual debris from a resolved infection.
How Spike Spreads Beyond the Original Source
The paper outlines several mechanisms by which spike from a small number of producer cells can reach a vastly larger number of healthy cells:
Extracellular vesicles (exosomes). Spike protein packaged inside exosomes can evade antibody neutralization. Antibodies can’t bind to what they can’t reach. These vesicles carry spike through circulation and into tissues, delivering it to cells that never encountered the virus directly. These are the same vesicles by which proposed spike protein shedding events occur.
Syncytia formation. When spike-expressing cells contact cells with ACE2 receptors, they can fuse, creating multinucleated structures. Each fusion event effectively transfers spike-producing capacity to multiple adjacent cells simultaneously. What does this mean? It means a single producer cell can transfect 5–20 neighbors in one fusion event.
Tunneling nanotubes (TNTs). Cells can form thin, direct membrane bridges to neighboring cells through which spike protein, vesicles, and potentially viral RNA can transit — entirely shielded from antibody neutralization. A spike-producing cell may maintain TNT connections with 5–50 neighboring cells at once.
The result is progressive tissue saturation: a small upstream source driving a disproportionately large downstream burden.
The Senescence Cascade
The senescence cascade is where the model becomes clinically relevant.
As cells accumulate spike protein intracellularly – whether through exosomal uptake, syncytia fusion, or TNT transfer – they experience proteostatic stress, ER stress, and DNA-damage-response signaling. Once these signals cross a threshold, the cell enters a state of irreversible growth arrest: cellular senescence. It stops dividing, resists programmed cell death, and begins producing a continuous stream of pro-inflammatory signals collectively called the SASP — the senescence-associated secretory phenotype.
But the most important feature of senescent cells is that their SASP is contagious.
SASP factors — IL-6, IL-8, IL-1β, TNF-family molecules, matrix metalloproteinases — induce senescence in neighboring cells that may contain no measurable spike antigen themselves. This bystander or paracrine senescence means the lesion expands far beyond the originally spike-exposed population. Cells that never encountered spike become senescent because they were next to cells that did.
This creates a self-amplifying cascade that the paper describes precisely: the disease can transition from a spike-driven initiation phase to a senescence-dominant maintenance phase. In this case, the symptom burden becomes partially decoupled from measurable spike load. Patients remain severely symptomatic even when standard tests don’t detect viral material, because the biology has “handed off” from an antigenic driver to a self-sustaining cellular program.
This is consistent with what we observe clinically in Long COVID patients who have been ill for two, three, or four years. It is also consistent with why therapies aimed purely at viral clearance often underperform in established disease.
Why Each Reinfection Layers Onto This Foundation
Each additional COVID exposure, whether from Cicada, any other variant, or a future strain, adds a new round of spike protein input to a system that is already struggling with ongoing production, progressive tissue saturation, and expanding senescent cell burden.
It replenishes the upstream source. A reinfection doesn’t just cause acute illness and then clear. It potentially seeds new producer cells, adds to the extracellular vesicle pool carrying spike, and re-exposes tissues that may have been recovering toward a threshold. The spike positivity data from the Vedicinals group’s European laboratory is consistent with this: a population of Long COVID patients showing rising, not declining, spike detection over time. Reinfections accelerate what was already an accumulating burden.
It compounds the senescence burden. Each new wave of spike-driven senescence induction is additive. Primary senescence from new spike exposure layers onto existing senescent cell populations. The paracrine cascade expands into new tissue territory. Patients who were at the margin of clinical stability (still functioning, managing their condition) can cross a tipping point following reinfection into significantly more impaired states.
The Cicada variant’s immune escape makes it more likely to establish a productive reservoir. For a Long COVID patient whose immune system is already dysregulated and whose neutralizing antibody response may be quantitatively or qualitatively impaired, a variant with enhanced antibody escape has a higher probability of establishing persistent producer cells rather than being rapidly cleared.
The spike protein variant may matter. The Vedicinals paper notes that earlier variants, including Omicron, appear to induce higher p16 and p21 expression (markers of cellular senescence) than ancestral strains, despite causing less severe acute illness. Cicada’s 70–75 spike mutations represent a distinct protein configuration. Whether this configuration affects senescence-induction kinetics is not yet established, but the direction of the existing data (that newer variants may be more senescence-inducing despite less acute severity) is something this patient population needs to take seriously.
The acute illness is not the danger. The downstream biology is.
This is the core message that is absent from every piece of mainstream Cicada variant coverage. The question “is it more severe?” is answered by hospitalization rates and ICU admissions. It does not capture what happens over the following 6, 12, or 18 months in someone already carrying significant senescent cell burden. It does not capture the cumulative cost of each reinfection to a biological system that has been running in a state of chronic dysregulation.
The Role of Senolytics: Reducing the Cost of Repeat Exposure
If the senescence cascade model is correct, and the evidence is increasingly consistent with it, then one of the most important things a Long COVID patient can do in the context of ongoing variant circulation is actively work to reduce their existing senescent cell burden. This reduces the foundation onto which a new exposure would layer, and it may limit the propagation of any new senescence cascade.
This is not a new clinical concept for us. Senolytic interventions (agents that selectively clear senescent cells) have been part of our treatment framework for Long COVID and Post-Vaccine Syndrome.
Some (but not all) clinically relevant therapies in this context include:
Intermittent fasting and autophagy promotion. The body’s cellular recycling program, autophagy, is one of the primary endogenous mechanisms for clearing dysfunctional cellular components. Caloric restriction and intermittent fasting protocols can meaningfully upregulate autophagy, and this can complement other senolytic approaches. However, as we’ve noted in our MCAS content, fasting protocols in Long COVID patients require clinical judgment. Not every patient can tolerate aggressive fasting, and the approach needs to be sequenced appropriately with other interventions.
Senomorphics — reducing SASP without clearing cells. For patients where aggressive senolytic dosing is not appropriate, senomorphic agents — those that reduce SASP output without necessarily clearing the senescent cells — can limit the paracrine propagation of the cascade. Low-dose rapamycin and metformin both have evidence in this area, and both are already used in relevant clinical contexts at our practice.
A 2021 study published in Science by Camell and colleagues provided direct evidence that senolytics reduce coronavirus-related mortality in aged mice, specifically by clearing the senescent cell burden that amplified the inflammatory response to viral infection. While this was in the context of acute infection rather than chronic Long COVID, the mechanism is directly relevant. Reducing pre-existing senescent cell burden before or after a new exposure limits how much the SASP-driven inflammatory cascade can amplify in response.
This is a clinically actionable implication. Patients with established Long COVID who maintain an ongoing senolytic protocol are not only treating their current disease, they are reducing the biological cost of the next inevitable exposure.
What This Means Practically for Long COVID and PACVS Patients Right Now
The COVID variant of the week is circulating in a population of Long COVID patients who are already carrying spike protein burden, established senescent cell populations, and a SASP-driven inflammatory environment.
The practical implications for this population are:
Reinfection prevention matters more for you than for the general population. Your risk includes compounding senescence, new producer cell seeding, potential tipping-point transitions in disease severity.
Senolytic maintenance is relevant timing. For patients already on senolytic protocols, ensuring adequate maintenance dosing during a period of active variant circulation is clinically sensible. For patients who have not yet incorporated senolytics into their treatment, this is a reasonable moment to discuss it with your provider.
Acute COVID treatment matters differently for you. If you do develop an acute Cicada infection, early intervention with antiviral therapy is relevant not primarily to prevent severe acute illness, but to limit the duration and magnitude of spike protein production, and therefore the new producer cell burden established during the infection. Shorter, lower-severity infection means less spike, means less new senescence induction.
The spike protein clearance and senolytic work you do now is investment against future exposures. Reducing your current spike burden and your current senescent cell load is not just about feeling better today, it is about building a lower biological baseline from which any future reinfection would cascade. This is why we treat Long COVID not as a single-point intervention but as an ongoing, evolving clinical relationship.
Conclusion: The Real Risk of Reinfection
The Cicada variant is being reported as “not more severe”. For the acute phase, that is accurate. But for the Long COVID and Post-Vaccine Syndrome patient, the frame of acute severity is inadequate.
The real risk of reinfection is not hospitalization. The real risk is what each additional exposure does to a biological system already operating under chronic spike pressure and expanding senescent cell burden. Each reinfection is not a reset. It is an addition to a running total that has consequences that unfold over months and years.
The senescence cascade hypothesis advanced by researchers at the Vedicinals group provides a mechanistic vocabulary for why patients experience progressive worsening over time despite no acute event. It explains why Long COVID symptoms can outlast any measurable marker of infection. And it clarifies what is at stake in the context of ongoing variant circulation.
This is the conversation that needs to be happening with Long COVID patients right now. At Leading Edge Clinic, it is the conversation we are having.
Leading Edge Clinic specializes in Long COVID, Post-Vaccine Syndrome, and complex post-infectious illness. Our providers treat patients across all 50 states via telehealth.
This article is for educational purposes and does not constitute medical advice.
Key References
Gerlach J, Baig AM, et al. Persistent Spike Protein Production and Progressive Tissue Saturation in Long COVID: Novel Hypothesis for a Senescence Cascade. Vedicinals Group / Health-Shield. 2025. [Preprint]
Camell CD, Yousefzadeh MJ, Zhu Y, et al. Senolytics reduce coronavirus-related mortality in old mice. Science. 2021;373:eabe4832. https://doi.org/10.1126/science.abe4832
Patterson BK, et al. Persistence of SARS-CoV-2 S1 protein in CD16+ monocytes in PASC up to 15 months post-infection. Front Immunol. 2021;12:746021. https://doi.org/10.3389/fimmu.2021.746021
Meyer K, et al. SARS-CoV-2 spike protein induces paracrine senescence and leukocyte adhesion in endothelial cells. J Virol. 2021;95:e00794-21. https://doi.org/10.1128/JVI.00794-21
Tsuji S, et al. SARS-CoV-2 infection triggers paracrine senescence and a sustained senescence-associated inflammatory response. Nat Aging. 2022. https://doi.org/10.1038/s43587-022-00170-7
Acosta JC, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15(12):1524–1535. https://doi.org/10.1038/ncb2871
Introduction: The Clotting Problem Most Doctors Aren’t Testing For
Many Long COVID and Post-Vaccine Syndrome patients know their symptoms. Fatigue that doesn’t resolve with rest. Brain fog that feels like you’re wading through muck just to formulate a coherent thought. Breathlessness that appears without warning. Chest tightness that comes and goes. Post-exertional crashes that wipe out any attempt at normal activity.
What most patients, and most clinicians, have come to know is that for a significant proportion of these patients, the blood itself is part of the problem.
Not in the dramatic, visible way that shows up on imaging. In a quieter, more insidious way: tiny, abnormal clots forming throughout the microvasculature, reducing oxygen delivery to tissues, trapping inflammatory molecules, and physically obstructing circulation in capillaries too small to show up on any standard scan. Amyloid fibrin microclots are not a novel issue. But, with spike protein, they are more significant than ever before. Not a single patient of ours comes to us with low levels of microclotting.
A critical aspect of microclotting we will explore in this article: a genetic variant that approximately 25–30% of the general population carries means some patients are dramatically more prone to forming these clots, and dramatically less able to clear them, than others.
Understanding this mechanism, and how your genetics interact with it, changes what treatment should look like. At Leading Edge Clinic, it’s something we assess in patients where microclotting is suspected as a significant driver. This post explains the underlying science and the clinical implications.
What Are Fibrin Amyloid Microclots?
Normal blood clotting is a tightly regulated process. When a vessel is injured, a soluble protein circulating in plasma called fibrinogen is converted to fibrin, forming a mesh-like clot that stops bleeding. Once the injury heals, an enzyme called plasmin dissolves the fibrin through a process called fibrinolysis. The clot clears. Normal circulation resumes.
In Long COVID and Post-Vaccine Syndrome, this process goes wrong in a specific and well-documented way.
Research pioneered by Professor Etheresia Pretorius at Stellenbosch University and Professor Douglas Kell at the University of Liverpool, beginning in 2021 and now confirmed across multiple independent research groups, has established that the spike protein of SARS-CoV-2 can trigger fibrinogen to misfold into an abnormal, amyloid-like form. These fibrinaloid microclots, the term used in the published literature, have structural properties that make them fundamentally different from normal clots.
Most critically: they resist normal fibrinolysis. The body’s standard clot-clearing machinery, plasmin, cannot effectively break them down.
What Makes These Microclots Different
Normal fibrin clots form a loose mesh that plasmin can penetrate and degrade. Amyloid fibrin microclots are densely compacted, beta-sheet rich structures. This is the same structural architecture seen in amyloid proteins associated with Alzheimer’s and Parkinson’s diseases. Plasmin can penetrate normal clots. It cannot efficiently dissolve amyloid fibrin.
Beyond their structural resistance, these microclots also trap inflammatory molecules within their matrix. Proteomics analysis by the Pretorius and Kell groups found that Long COVID microclots contain elevated levels of pro-inflammatory proteins, complement activation markers, and von Willebrand factor — creating what amounts to mobile packages of inflammatory material that continuously activate the immune system wherever they circulate.
A 2022 landmark paper by Kell, Laubscher, and Pretorius in the Biochemical Journal formally established microclots as a central driver of Long COVID pathology, noting that these structures persist in the plasma of Long COVID patients even when they are not in an active clotting event. They circulate freely, obstructing capillaries, and sustaining a chronic inflammatory state.
More recent research published in the Journal of Medical Virology (2025) confirmed that microclots in Long COVID patients are structurally associated with neutrophil extracellular traps (NETs), providing another mechanism by which they perpetuate thromboinflammation and immune dysregulation.
The Symptoms Microclotting Produces
The capillary bed is where oxygen, nutrients, and cellular waste products are exchanged between blood and tissues. When microclots obstruct these vessels, the consequences are predictable:
Fatigue and post-exertional malaise: Reduced oxygen delivery to muscles and mitochondria
Brain fog and cognitive dysfunction: Impaired cerebral microcirculation
Breathlessness and exercise intolerance: Reduced pulmonary capillary perfusion
Small fiber neuropathy and tingling: Nerve tissue hypoxia from microvascular obstruction
Temperature dysregulation: Peripheral microcirculatory dysfunction
These are among the most commonly reported and most treatment-resistant symptoms in Long COVID. For patients where microclotting is a significant driver, failing to address it means failing to address a foundational cause of their persistent symptoms. Of course, these symptoms can have other potential driving factors that also must be addressed, such as MCAS, chronic Cell Danger Response, POTS, and more.
PAI-1: The Body’s Clot-Clearing Brake
To understand why some patients are far more vulnerable to persistent microclotting than others, you need to understand a protein called Plasminogen Activator Inhibitor-1, or PAI-1.
PAI-1 is the primary regulator of fibrinolysis, the clot-clearing process. Its job is to inhibit the enzymes (tissue plasminogen activator, or tPA, and urokinase plasminogen activator, or uPA) that convert plasminogen into plasmin, the enzyme that dissolves fibrin. In other words, PAI-1 is the brake on clot dissolution.
This braking function is necessary. The body doesn’t want clots dissolving prematurely when they’re serving a purpose (ie: stopping bleeding). But in a context where amyloid microclots are forming continuously and need to be cleared as quickly as possible, excessive PAI-1 activity is a serious problem. It keeps the brake partially applied when you need full fibrinolytic capacity.
And here’s where genetics becomes directly clinically relevant.
The PAI-1 4G/5G Polymorphism: A Genetic Modifier of Microclotting Risk
In the promoter region of the SERPINE1 gene, the gene that encodes PAI-1, there is a well-characterized genetic variant called the 4G/5G polymorphism. This refers to a single position in the DNA sequence where individuals carry either four consecutive guanosine bases (4G) or five (5G).
This small difference has significant functional consequences for how much PAI-1 your cells produce.
The Three Genotypes
The 4G/5G polymorphism produces three possible genotypes:
4G/4G (homozygous 4G): Both copies of the gene carry the 4G allele. The 5G allele has an additional transcriptional repressor binding site that reduces PAI-1 gene expression — the 4G allele lacks this site. Carrying two 4G alleles means higher baseline PAI-1 production, suppressed fibrinolysis, and significantly elevated thrombosis risk. Under inflammatory conditions, including COVID-19 infection and spike protein exposure, PAI-1 production in 4G/4G individuals ramps up further and is more difficult to suppress.
4G/5G (heterozygous): One copy of each allele. PAI-1 levels are intermediate. Research shows that inflammatory signals like IL-1β still enhance PAI-1 production in 4G/5G endothelial cells, though less dramatically than in 4G/4G individuals.
5G/5G (homozygous 5G): Both copies carry the 5G allele. Lowest baseline PAI-1 production, most active fibrinolysis. However, and this is a crucial nuance, 5G/5G individuals have a different risk profile in COVID-19 contexts. With the fibrinolytic brake released, these patients can develop overactive fibrinolysis and inflammation-driven endothelial dysfunction through a different mechanism.
A 2024 study published in Frontiers in Immunology by Yatsenko, Heissig, and colleagues at Juntendo University confirmed these distinct mechanistic profiles in COVID-19 patients, finding that 4G/4G individuals showed high circulating PAI-1 complexed with plasminogen activators, low plasmin levels, and NF-κB upregulation – a pattern of fibrinolytic shutdown under inflammatory conditions. The 5G/5G group showed the opposite: lower PAI-1, elevated free plasminogen activators, and a profile of inflammation-driven endothelial dysfunction.
Population Prevalence
The 4G allele is common. Population genetics research suggests approximately:
25–30% of people carry the 4G/4G genotype
50% carry the 4G/5G heterozygous genotype
20–25% carry the 5G/5G genotype
This means roughly half to three-quarters of the general population carries at least one 4G allele — and among patients with severe, persistent Long COVID, this proportion may be even higher given the known interaction between the 4G allele and spike protein-driven inflammatory signaling.
Why This Matters Clinically: Two Different Problems, Two Different Approaches
The clinical significance of the 4G/5G polymorphism is not merely academic. It has direct implications for how microclotting should be treated in individual Long COVID and Post-Vaccine Syndrome patients, and why a uniform anticoagulation approach for all patients is inadequate.
The 4G/4G Patient: Fibrinolytic Suppression
For patients with the 4G/4G genotype, the central problem is that spike protein-driven inflammation severely suppresses fibrinolysis. PAI-1 rises under inflammatory conditions, plasmin activity is reduced, and the body’s capacity to clear microclots is significantly impaired.
In these patients, the therapeutic priority is: reduce PAI-1 activity and/or directly enhance fibrinolysis. This is where fibrinolytic enzymes – nattokinase, lumbrokinase – become particularly relevant. Both enzymes work through mechanisms that directly counter the 4G/4G problem.
Nattokinase is a serine protease derived from fermented soybeans (natto) that works through two complementary mechanisms: it directly cleaves fibrin, and it inactivates PAI-1 — the precise molecular target that is overexpressed in 4G/4G patients. Research published in the Journal of Agricultural and Food Chemistry demonstrated that nattokinase directly hydrolyzes PAI-1, increasing fibrinolytic activity. The combination of direct fibrin cleavage and PAI-1 inhibition makes it particularly well-suited to the 4G/4G mechanism.
Lumbrokinase, derived from earthworm species, operates through direct fibrinolytic action and plasminogen activator stimulation. Research by the PolyBio Research Foundation has initiated a clinical trial specifically examining lumbrokinase in Long COVID and ME/CFS, reflecting the growing clinical and mechanistic case for fibrinolytic enzymes in microclot-driven post-viral illness.
Beyond enzymes, sulodexide – a glycosaminoglycan with both anticoagulant and endothelial-protective properties – is used in our practice for patients with evidence of microclotting and endothelial involvement. Unlike systemic anticoagulants, sulodexide has a favorable safety profile for longer-term use and directly supports endothelial repair, which is important given that endothelial dysfunction is both a consequence of microclotting and a driver of further PAI-1 elevation.
The 5G/5G Patient: Inflammation-Driven Endothelial Dysfunction
For patients with the 5G/5G genotype, the problem is different. Fibrinolysis is not suppressed, but inflammation-driven endothelial dysfunction creates a prothrombotic state through other pathways, including elevated uPA and activated complement. These patients may be more prone to systemic inflammation and immune dysregulation than to pure fibrinolytic failure.
The 2024 Juntendo University study specifically identified 5G/5G patients as being at risk for inflammation-induced endothelial dysfunction with fibrinolytic overactivation, a phenotype where aggressive fibrinolytic therapy carries different risk considerations and where anti-inflammatory and endothelial-supportive strategies may be the more appropriate primary focus.
This is clinically significant: the 5G/5G patient who receives high-dose fibrinolytic enzymes without consideration of their genotype is receiving a treatment rationale designed for a different problem. Anticoagulation approach needs to be matched to mechanism, not applied uniformly.
The 4G/5G Patient: Intermediate Risk, Moderate Response
Heterozygous patients show an intermediate profile. The Juntendo study found that IL-1β still enhances PAI-1 production in 4G/5G endothelial cells, though less severely than in 4G/4G. These patients benefit from fibrinolytic support but may need less aggressive dosing and may respond well to lower-intensity anticoagulation combined with strong anti-inflammatory support.
Testing: What We Look For and When
Knowing a patient’s PAI-1 genotype is straightforward. It can be obtained through standard genetic testing including Labcorp’s PAI-1 4G/5G Polymorphism panel (test code 500309).
Beyond genotype, we also look at functional markers of clotting and fibrinolytic activity when clinically indicated:
PAI-1 functional activity levels (plasma)
D-dimer (marker of ongoing fibrin degradation — elevated in active microclotting)
Fibrinogen levels
Von Willebrand factor antigen (marker of endothelial activation)
Microclotting levels through fluorescence microscopy
Importantly, standard blood tests and imaging do not detect microclots. The specialized fluorescence microscopy techniques used in Pretorius’s laboratory research are not commercially available at just any lab. We are able to offer this testing to our patients.
This is an area where pattern recognition from clinical experience matters significantly. The presentation of a patient with 4G/4G genotype, elevated D-dimer, elevated fibrinogen, and symptoms strongly suggestive of microvascular obstruction tells a coherent story that guides a different treatment approach than a patient with 5G/5G genotype and primarily inflammatory, autonomic symptoms.
The Broader Picture: Microclotting Doesn’t Operate in Isolation
It’s important to place microclotting in the context of Long COVID’s full complexity. Persistent microclots are a significant mechanism for many patients, but they rarely operate alone. They interact with and compound other pathophysiological drivers:
Microclotting and Cell Danger Response: Tissue hypoxia from microvascular obstruction can itself activate and sustain the Cell Danger Response. Cells detect oxygen insufficiency as a threat and shift into the protective metabolic state we discussed in our CDR post. Addressing microclotting may be a necessary prerequisite to allowing the CDR to resolve in some patients.
Microclotting and POTS/Dysautonomia: Endothelial dysfunction from microclotting directly affects autonomic regulation of vascular tone. Many patients with post-COVID POTS have a vascular endothelial component to their dysautonomia that won’t fully resolve without addressing the underlying endothelial damage.
Microclotting and Neurological Symptoms: The 2025 Journal of Medical Virology study confirmed that microclots in Long COVID are structurally associated with NETs markers, including myeloperoxidase and neutrophil elastase, which can themselves cross the blood-brain barrier and contribute to neuroinflammation. Brain fog in these patients has a partially vascular etiology, not just neurological.
Microclotting and Senescent Cells: Chronic endothelial damage from persistent microclotting can itself drive cellular senescence in vascular endothelial cells, creating a feedback loop where senescent endothelial cells produce SASP-driven pro-inflammatory and pro-thrombotic signals that generate more clotting. This interaction is one reason why microclotting in some patients is difficult to resolve without simultaneously addressing cellular senescence.
The clinical implication is that microclotting treatment is rarely sufficient as a standalone intervention. It typically needs to occur in parallel with reducing the spike protein burden that is driving fibrinogen misfolding, addressing the inflammatory environment that elevates PAI-1, and supporting the endothelial repair that allows normal fibrinolytic function to resume.
A Note on Safety and Clinical Oversight
Fibrinolytic therapy, whether enzymatic or pharmaceutical, requires appropriate clinical supervision. The primary risk is bleeding, and the probability of this risk increases meaningfully when fibrinolytic agents are combined with pharmaceutical anticoagulants (aspirin, clopidogrel, apixaban, warfarin, heparin) without careful monitoring.
This is not an argument against fibrinolytic treatment. We have treated over a thousand patients with triple anticoagulation therapy combined with enzymatic therapies. It is an argument for doing it with proper clinical oversight, appropriate dosing based on individual presentation and genotype, and awareness of the full medication picture. The patients who have the worst outcomes with DIY fibrinolytic protocols are typically those combining multiple agents without understanding their additive effects. Not only that, they are not dealing with the complete picture of spike protein injury.
At Leading Edge Clinic, anticoagulation approach is individualized to the patient’s genetic profile, symptom presentation, functional markers, and complete medication list. For some patients, nattokinase alone at appropriate dosing is the right starting point. For others, sulodexide plays a primary role. For a smaller number of patients with more significant microclotting burden and appropriate clinical indicators, pharmaceutical anticoagulation is warranted. There is no universal protocol.
Conclusion
Fibrin amyloid microclots represent one of the most mechanistically coherent and clinically important, yet most frequently missed, drivers of persistent Long COVID and Post-Vaccine Syndrome symptoms. They explain a cluster of symptoms (fatigue, brain fog, breathlessness, post-exertional malaise) that don’t respond to anti-inflammatories alone because the problem isn’t only inflammation. The problem is physical obstruction of microcirculation and ongoing thromboinflammation.
And the PAI-1 4G/5G polymorphism explains something that purely inflammation-focused frameworks can’t: why patients with similar spike protein exposure and similar inflammatory burdens have dramatically different microclotting trajectories. Your genetics determine how effectively your body can clear these abnormal clots, and they should determine how you treat them.
This is the kind of individualized, mechanism-informed clinical reasoning that drives our approach at Leading Edge Clinic. If you’re experiencing symptoms consistent with microclotting and you haven’t been evaluated for fibrinolytic capacity or PAI-1 genotype, that may be a meaningful gap in your care picture.
Leading Edge Clinic specializes in Long COVID, Post-Vaccine Syndrome, and complex post-infectious illness. Our providers treat patients across all 50 states via telehealth. Initial evaluations are 60 minutes.
This article is for educational purposes and does not constitute medical advice. Fibrinolytic therapy carries clinical risks and should be undertaken only with appropriate medical supervision.
Key References
Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022;479(4):537–559. https://pmc.ncbi.nlm.nih.gov/articles/PMC8883497/
Yatsenko T, et al. The influence of 4G/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction. Front Immunol. 2024;15:1445294. https://pmc.ncbi.nlm.nih.gov/articles/PMC11392769/
Pretorius E, et al. Persistent clotting protein pathology in Long COVID/PASC is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20:172. https://doi.org/10.1186/s12933-021-01359-7
Thierry AR, et al. Circulating microclots are structurally associated with neutrophil extracellular traps and their amounts are elevated in Long COVID patients. J Med Virol. 2025;97:e70613. https://pmc.ncbi.nlm.nih.gov/articles/PMC12489976/
Kruger A, et al. Proteomics of fibrin amyloid microclots in Long COVID/PASC shows many entrapped pro-inflammatory molecules. Cardiovasc Diabetol. 2022;21:190. https://doi.org/10.1186/s12933-022-01623-4
You went to your primary care doctor. They ran the standard panels, found nothing, and told you to rest. You pushed. Through endless research and self-advocacy, you found a Long COVID clinic – maybe a university program, maybe a telehealth practice, maybe an integrative specialist someone in your online support group recommended. You spent a significant amount of money on testing and extensive protocols, waiting to get better.
You’re still sick.
If that describes your experience, this post is for you. Our goal is to honestly explain something that most Long COVID and Post-Vaccine Syndrome clinicians — even well-meaning, intelligent ones — fundamentally misunderstand about this condition.
At Leading Edge Clinic, we’ve treated more than 3,500 patients with Long COVID and Post-Vaccine Syndrome. Many of them came to us after failing at other practices, sometimes after spending $30,000 to $100,000 elsewhere. What we’ve observed over years of clinical work has shaped a different understanding of why standard approaches so often fall short.
The Core Problem: Long COVID Is Not One Disease
The most common clinical mistake we see, across conventional medicine, integrative medicine, and Long COVID specialty practices alike, is treating this condition as if it has a singular mechanism that responds to a singular approach (ie: dealing only with spike persistence, dealing only with immune dysfunction, looking only at gut health, etc…)
It doesn’t.
Long COVID and Post-Vaccine Syndrome are multi-system, multi-mechanism conditions that present differently in every patient and evolve over time. What’s driving your fatigue may not be the same as what’s driving the next patient’s. And critically, what’s driving your symptoms today may not be what’s driving them six months from now.
Like other historicaly post-viral and post-vaccine syndromes, this not a simple infection with a clean recovery arc. It is a dysregulated biological state, and it is very effcient at driving that dysregulated state — often involving the immune system, the nervous system, the vascular system, and the metabolic system simultaneously, in proportions that vary person to person and shift in response to treatment.
A clinician who approaches it with a fixed protocol, even a sophisticated one, is going to miss the mark for a significant portion of patients.
What Standard Approaches Miss
This is not an exhaustive list. It hits on some major systemic issues we don’t see others talking about, but these aren’t the only things we see other clinicians missing when a new patient comes to us that has tried elsewhere first.
1. They Don’t Account for Cell Danger Response
One of the most underappreciated mechanisms in Long COVID is something called the Cell Danger Response (CDR) — a concept developed by metabolic researcher Dr. Robert Naviaux.
The CDR is the body’s ancient, conserved response to threat. When cells detect danger, such as infection, toxin, or injury, they shift into a defensive metabolic state. Energy production is reduced, cellular communication slows down , and cells essentially go quiet to protect themselves.
This is adaptive in the short term. After an acute COVID infection, you want this response. It’s doing its job.
The problem is when the CDR doesn’t turn off. When the body’s threat detection system remains activated long after the initial danger has passed, you get persistent metabolic suppression. This manifests as fatigue that doesn’t resolve with rest, cognitive dysfunction that doesn’t respond to sleep, and a nervous system that stays in a low-grade defensive posture.
Most Long COVID clinicians are not testing for or thinking about CDR biology. Many deal with chronic inflammation and persistent spike protein, but never take that next step to address chronic CDR.
2. They Don’t Understand Senescent Cells
Cellular senescence, what some researchers call the “zombie cell” problem, is another mechanism that rarely appears in standard Long COVID treatment frameworks, although it may accidentally be addressed (albeit not thoroughly enough) through treatments with other prescribed purposes.
Senescent cells are cells that have stopped dividing but refuse to die. In the aftermath of a severe immune activation like COVID infection, the body can accumulate these cells in significant numbers. In fact, the spike protein seems to have be very skilled at producing senescent cells. These cells don’t do their normal jobs, but they also release a continuous stream of pro-inflammatory signaling molecules, the senescence-associated secretory phenotype (or SASP).
The result of senescent cell accumulation is a low-grade, chronic inflammatory state that can persist for years. Standard anti-inflammatory approaches don’t clear senescent cells. Senolytics, which are treatments that induce apoptosis in senescent cells, are rarely considered in clinical practice, let alone in Long COVID or Post-Vaccine Syndrome.
For patients where senescent cell burden is a significant contributor, which is all spike protein patients, treating everything else while ignoring this mechanism is like bailing water from a boat without fixing the leak.
3. They Apply Uniform Protocols to Non-Uniform Patients
We understand why this happens. Protocols are efficient. They can be standardized, taught, and scaled. If you’re running a practice that sees 50 Long COVID patients a week, a decision tree makes sense. Our practice model focuses on lower patient volumes for more personalized care and treatment. Why?
Long COVID patients are not uniform. The neurotransmitter profile of one patient – the specific pattern of catecholamine deficiency, glutamate dysregulation, and kynurenine pathway disruption – may look nothing like the next patient’s. The autoimmune burden, the degree of microclotting, the level of residual spike protein activity, the autonomic dysfunction pattern, may all vary enormously from patient to patient.
Our practice partner Scott Marsland, FNP-C, published a detailed case study that illustrates this complexity in just one patient, examining neurotransmitter changes across time and in response to specific interventions. The data showed 13 of 27 measured neurotransmitters were outside optimal range at baseline. The specific pattern of elevated glutamate suggesting excitotoxicity, paradoxically elevated serotonin alongside low tryptophan, and depleted catecholamines required a tailored response, not a standard protocol. And the picture changed meaningfully over seven months, requiring ongoing adjustment.
That is what individualized Long COVID care actually looks like.
4. They Over-Test and Under-Treat
There are particular kind of specialty practices that run $2,000–$5,000 in laboratory panels before doing much of anything. The testing is framed as “comprehensive” and “data-driven.” It feels thorough. As humans, we want to latch onto something concrete, like lab results. It gives us something to work at, and improve upon.
But here’s the honest clinical reality: in most Long COVID and PACVS patients, extensive testing rarely changes the initial treatment approach. The patterns we see across 3,500+ cases are recognizable. The likely mechanisms become apparent through careful history, symptom characterization, and clinical pattern recognition long before any lab results return.
Excessive testing delays treatment. It costs patients money they could have spent on interventions. And it creates an illusion of certainty in a condition that requires the intellectual honesty to acknowledge: we are treating this by thoughtful trial, observation, and adjustment. Running a panel and following a chart does not work for complex conditions like Long Covid and Post-Vaccine Syndrome. One day might turn up a normal lab result, and then many abnormalities the next testing period. Patients end up chasing ghosts.
And, by the way, if and when a $4,000 testing panel arrives that meaningfully guides pin-pointed treatment decisions tha deliver results, we will be the first ones to come back and edit this post.
5. They Treat the First Layer and Stop
Long COVID recovery, when it happens, typically unfolds across 9 to 18 months. Sometimes longer. The condition does not resolve in a single treatment arc, but requires ongoing attention to how the patient’s picture is shifting.
A treatment that was appropriate in month two may need modification by month five. An intervention that wasn’t relevant initially may become important as other issues resolve and different mechanisms become more apparent. The clinical work is iterative.
Many practices, particularly those operating at high volume or on a brief-consultation model, don’t have the infrastructure or clinical philosophy to support this. They prescribe an initial regimen and check in only when you schedule your next appointment. That interval is too long, and the flexibility to pivot is often not there.
What a Different Approach Looks Like
We want to be direct about what we actually do differently, not just what we criticize.
We start with clinical reasoning, not a panel. The first consultation at Leading Edge Clinic is 60 minutes. We are building a detailed picture of your symptom history, your illness trajectory, what you’ve tried, how you responded, and what the pattern suggests. That reasoning guides our initial approach, not a lab panel.
We think about mechanisms, not just symptoms. If you have fatigue, we want to understand whether it’s primarily metabolic, autonomic, inflammatory, or driven by a cellular danger response that hasn’t resolved. Different mechanisms call for different interventions.
We are honest about the trial-and-error nature of treatment. We don’t tell patients we’ve found the answer and here it is. We tell them: here is our best clinical hypothesis, here is the treatment we think is most likely to move things in the right direction, and here is how we’ll know if it’s working. We adjust based on what we observe.
We treat the evolving patient, not the initial presentation. Follow-up is built into how we work. As patients respond, we incorporate that information and adapt.
We consider mechanisms that others don’t. Cell danger response, cellular senescence, persistent spike protein activity, microclotting, neurological changes, autonomic dysfunction, immune dysregulation, MCAS, and other spike protein pathologies are all part of our clinical thinking. Not for every patient, but for the patients where these mechanisms are relevant, addressing them can be the difference between continued decline and meaningful recovery.
What You Should Ask Any Long COVID Specialist
If you’re evaluating whether a Long COVID practice is right for you, here are honest questions worth asking:
“What do you think is driving my specific symptoms?” A clinician who can give you a mechanistic hypothesis, specific to your history, and not a generic answer, is thinking carefully. A clinician who gives you the same answer they give everyone is running a protocol.
“What do you do when a treatment isn’t working?” The answer should involve active pivoting, consideration of alternative mechanisms, and willingness to try something different.
“How do you think about conditions like cell danger response or cellular senescence?” You’re not expecting a dissertation. But a blank look or a dismissive response tells you something about the depth of the clinical framework.
“How long do you expect treatment to take?” Honesty here matters. Anyone promising significant recovery in 6 to 8 weeks is either treating very mild cases or not being straight with you. The realistic timeline for meaningful improvement in complex Long COVID is 9 to 18 months.
A Note on What We Don’t Promise
We’ve seen enough patients and enough trajectories to say this plainly: approximately 80–85% of our patients achieve significant functional improvement over the course of treatment. That is a meaningful number, and we’re proud of it.
But 80–85% also means that 15–20% of patients don’t reach that threshold, at least not within our treatment window.
What we can promise is clinical honesty, genuine intellectual engagement with your case, and a willingness to keep thinking when the obvious approaches aren’t working.
If You’ve Already Tried Everything
If you’ve been through the conventional system, the university Long COVID clinics, the integrative medicine practices, the telehealth protocols – and you’re still significantly impaired – there may be value in a clinical framework that explicitly accounts for the mechanisms most others aren’t addressing.
We recognize that many of our patients come to us precisely because they’ve exhausted the obvious options and need something different.
A 60-minute initial evaluation gives us the opportunity to build a complete picture of your case: what you’ve tried, how you responded, what your symptom pattern suggests, and where we think there may be unexplored mechanistic territory. From that, we develop a realistic treatment roadmap, not a protocol applied to a category, but a clinical plan developed for your specific situation.
Long COVID and Post-Vaccine Syndrome not one disease. They don’t have one mechanism, they don’t respond to one protocol, and they don’t resolve on a predictable timeline.
The clinicians who are having the best outcomes with this condition are the ones who understand complexity, think in terms of mechanisms, are willing to adapt, and have the clinical experience to recognize patterns that don’t fit neatly into any category.
That is the medicine we practice. If you’ve been failed by other approaches and you’re still looking for meaningful progress, we’d be glad to talk.
Leading Edge Clinic specializes in Long COVID, Post-Vaccine Syndrome, and complex post-infectious illness. Our clinic has treated more than 3,500 patients with these conditions.
This article is for informational purposes and does not constitute medical advice. Individual results vary.
If you’ve spent any time researching repurposed drugs for cancer, you’ve almost certainly come across fenbendazole. The story of Joe Tippens, a terminal lung cancer patient who attributed his remission to a veterinary deworming drug, caught massive attention in 2019 and hasn’t stopped circulating since. More recently, Mel Gibson’s appearance on The Joe Rogan Experience, where he described friends beating Stage 4 cancers with fenbendazole and ivermectin, pushed the conversation further into the mainstream.
Before the Gibson interview on January 9th 2025, we had been steadily trodding along, a year into our adjunctive cancer program and participation in the Rebuild Medicine observational study. We were already well aware of the power of ivermectin and benzimidazoles.
Cancer patients, especially those with advanced disease who’ve exhausted conventional options, are looking for anything with a reasonable safety profile and a plausible mechanism. And the science behind benzimidazole anthelmintics as anticancer agents is real and growing. We have seen it first-hand, with our patients experience meaningful results, including remissions, through a multi-targeted program using a combination of repurposed drugs – including benzimidazoles. Dr. Kory documented similar successes to Joe Tippens’ story on his substack, detailing 5 patient case studies of Stage 4 Lung Cancer patients.
But here’s what gets lost in the excitement: fenbendazole is not the only benzimidazole, and it may not be the best one for cancer patients. In our clinical practice, we recommend mebendazole over fenbendazole, and not because mebendazole has a better marketing story. The reasons are pharmacological, clinical, and cautionary.
This article covers the benzimidazole drug class, the shared anticancer mechanisms that make them a must-have in our adjunctive cancer program, and why the choice between these drugs matters more than most online discourse acknowledges.
What Are Benzimidazoles?
Benzimidazoles are a class of anthelmintic (anti-parasitic) drugs that share a common chemical structure: a benzene ring fused with an imidazole ring. The class includes several drugs relevant to cancer research:
Mebendazole (MBZ): Approved for human use. Used to treat pinworm, roundworm, hookworm, and other parasitic infections. Available from compounding pharmacies.
Fenbendazole (FBZ): Approved for veterinary use. Commonly used in dogs, cats, and livestock. Not approved for human use by the FDA.
Albendazole (ABZ): Approved for human use. Primarily used for echinococcosis and neurocysticercosis. Less studied for cancer applications than mebendazole.
All three share the same core mechanism of action—they bind to β-tubulin and disrupt microtubule formation. This is why their anticancer properties overlap significantly. But they are not identical drugs. Their pharmacokinetics, bioavailability, polymorphic forms, regulatory status, and clinical track records in cancer patients differ in ways that have real consequences for patient outcomes.
How Benzimidazoles Fight Cancer: Shared Mechanisms
The anticancer activity of benzimidazoles has been demonstrated across dozens of preclinical studies and is now supported by an emerging clinical evidence base. Dr. Paul Marik classifies the mebendazole/fenbendazole/albendazole group as Tier One repurposed drugs in his comprehensive cancer care monograph (Marik, 2024)—meaning there is strong recommendation based on the available evidence.
The mechanisms are multi-targeted and address several cancer hallmarks simultaneously.
1. Microtubule Disruption and Mitotic Arrest
This is the foundational mechanism and the one benzimidazoles were essentially designed for, albeit against parasites, not cancer.
Microtubules are structural proteins that form the “skeleton” of dividing cells. During cell division (mitosis), microtubules organize into the mitotic spindle, which pulls chromosomes apart so each daughter cell gets a complete copy of DNA. Cancer cells divide rapidly and depend heavily on functional microtubules to do so.
Benzimidazoles bind to β-tubulin and prevent it from polymerizing into microtubules. Without functional microtubules, the mitotic spindle cannot form, and cell division arrests. Cells stuck in mitotic arrest eventually undergo apoptosis (programmed cell death).
This is the same general mechanism used by taxane chemotherapy drugs (paclitaxel, docetaxel) and vinca alkaloids (vincristine, vinblastine), except benzimidazoles achieve it at a fraction of the toxicity and cost.
In comparative screenings, mebendazole has demonstrated the greatest inhibitory effect among benzimidazoles tested against cancer cell lines, with IC50 values of 0.30–0.32 µM in chemoresistant melanoma cells—compared to 0.7–1.2 µM for albendazole and 1.2–1.4 µM for fenbendazole (Doudican et al., 2008). Importantly, mebendazole showed significantly less toxicity to normal melanocytes, demonstrating selectivity for cancer cells.
2. p53 Reactivation and Apoptosis Induction
The p53 tumor suppressor gene, often called the “guardian of the genome”, is the most commonly mutated gene in human cancers. When functional, p53 detects DNA damage and either halts cell division for repair or triggers apoptosis if the damage is irreparable. In many cancers, p53 is suppressed or rendered non-functional by overexpression of its negative regulators, MDM2 and MDMX.
Benzimidazoles have been shown to downregulate both MDM2 and MDMX, effectively restoring p53 function in tumor cells where p53 itself remains intact but is being suppressed (Mrkvová et al., 2019). This reactivation of p53 shifts the balance from uncontrolled proliferation back toward programmed cell death.
The upregulation of p53 and its downstream target p21 has been demonstrated for both mebendazole and fenbendazole (Dogra et al., 2018; Doudican et al., 2008), confirming this as a class-level effect.
3. Metabolic Disruption: Targeting the Warburg Effect
Cancer cells are metabolic parasites (not literal parasites, though). Rather than relying on efficient mitochondrial oxidative phosphorylation like healthy cells, most cancer cells depend heavily on glycolysis, fermenting glucose even in the presence of oxygen. This metabolic reprogramming, known as the Warburg effect, is now recognized as a fundamental hallmark of cancer and the basis for the metabolic theory of cancer as articulated by Thomas Seyfried and others.
Benzimidazoles inhibit glucose uptake and glycolytic enzymes in cancer cells, starving them of their primary fuel source (Pantziarka et al., 2014). This metabolic disruption is particularly relevant in the context of a ketogenic dietary intervention, a strategy we employ – when indicated – alongside repurposed drug protocols at our practice. When you restrict glucose availability through diet and simultaneously block cancer cells’ ability to import what glucose remains, you create a hostile metabolic environment that healthy cells can adapt to, but cancer cells cannot.
4. Cancer Stem Cell Targeting
Cancer stem cells (CSCs) are the subpopulation of cells within a tumor responsible for treatment resistance, recurrence, and metastasis. They are the reason cancers come back after chemotherapy appears to have worked. Conventional cytotoxic treatment kills the bulk tumor cells while leaving the CSCs intact.
This is one of the central differentiators of our adjunctive cancer care program: we target cancer stem cells directly, while conventional treatment largely does not.
Benzimidazoles target CSCs through multiple pathways:
Sonic Hedgehog/GLI1 inhibition: Mebendazole inhibits the Hedgehog signaling pathway—a major driver of cancer stem cell self-renewal—at IC50 of 0.516 µM, positioning it as a potential alternative to the pharmaceutical Hedgehog inhibitor vismodegib (Borodovsky et al., 2015).
ALDH+ stem cell depletion: Mebendazole depletes ALDH+ cancer stem cells in triple-negative breast cancer, one of the most aggressive and difficult-to-treat subtypes (Targeting CSCs, as reviewed in Marik, 2024).
Wnt/β-catenin pathway suppression: Both mebendazole and fenbendazole interfere with Wnt signaling, which is critical for CSC maintenance and self-renewal across multiple cancer types.
When combined with ivermectin, which targets CSCs through complementary mechanisms (PAK1/Akt/mTOR blockade, downregulation of NANOG/SOX2/OCT4), the benzimidazole-ivermectin combination provides multi-pathway CSC coverage. This is why we typically recommend both drugs together as part of a comprehensive protocol. Furthermore, we do not recommend these drugs as monotherapies.
5. Anti-Angiogenic Effects
Tumors require a blood supply to grow. The process of recruiting new blood vessels, angiogenesis, is driven largely by vascular endothelial growth factor (VEGF) signaling. Mebendazole reduces VEGFR2 kinase activity and decreases tumor microvessel density in preclinical models, effectively cutting off the tumor’s supply lines (Pantziarka et al., 2014).
This anti-angiogenic property complements the metabolic disruption described above: you’re simultaneously restricting the tumor’s fuel delivery (angiogenesis inhibition) and its ability to use that fuel (glycolysis inhibition).
6. Immune Modulation
Emerging research demonstrates that mebendazole polarizes tumor-associated macrophages from the immunosuppressive M2 phenotype toward the pro-inflammatory M1 phenotype (as reviewed in Marik, 2024). In simple terms: tumors actively suppress local immune cells to avoid detection. Mebendazole helps reverse that suppression, re-enabling the immune system to recognize and attack cancer cells.
This immune-modulating effect is particularly interesting in the context of combination protocols, as it may enhance the activity of other immunomodulatory agents in the regimen, including low-dose naltrexone, which several of our cancer patients also use.
7. BRAF/MEK Pathway Inhibition
Mebendazole inhibits the BRAF/MEK signaling pathway, including the BRAF V600E mutation, one of the most common oncogenic mutations, found in approximately 50% of melanomas and a significant percentage of colorectal, thyroid, and lung cancers. This gives mebendazole a targeted therapy-like mechanism in addition to its broader anticancer effects.
Blood-Brain Barrier Penetration: A Critical Advantage for Mebendazole
One of mebendazole’s most clinically significant properties is its ability to cross the blood-brain barrier (BBB).
Bai et al. (2015) demonstrated in preclinical glioblastoma models that mebendazole achieves therapeutically effective concentrations in brain tissue and tumor. However – and this is critical – not all forms of mebendazole are equal in this regard.
Mebendazole exists in three polymorphic forms: A, B, and C. These are chemically identical but differ in their crystal structure, which affects how they dissolve, absorb, and distribute in the body.
Polymorph C reaches therapeutic concentrations in brain tissue with fewer side effects than polymorphs A or B (Bai et al., 2015). In the preclinical glioblastoma study, polymorph C significantly extended survival, and its efficacy was further enhanced when combined with elacridar (a drug that inhibits the P-glycoprotein efflux pump at the BBB).
Polymorph A showed inferior brain penetration and reduced anticancer efficacy compared to polymorph C.
Polymorph B is the least bioavailable form and is generally considered subtherapeutic for cancer applications.
This distinction matters enormously for patients, and it’s one that most online fenbendazole resources don’t address because fenbendazole doesn’t have this level of polymorphic characterization in human pharmacokinetic studies. If you’re taking mebendazole for cancer and you’re not receiving polymorph C, you may not be getting therapeutic benefit. This is why we recommend obtaining mebendazole from compounding pharmacy partners who can verify polymorph C formulation through 3rd party lab testing, rather than purchasing international products where the polymorphic form is uncertain. This is also why we work with trusted compounding pharmacy partners.
Why We Recommend Mebendazole Over Fenbendazole
Given that benzimidazoles share a core mechanism of action, why does the specific drug choice matter? Several reasons:
1. Human Pharmacokinetic Data
Mebendazole has decades of human pharmacokinetic data from its approved use treating parasitic infections, including long-term, high-dose studies in echinococcosis patients (40–50 mg/kg/day for months to years). This gives clinicians a well-characterized safety profile with known drug interactions, metabolism pathways, and adverse effect patterns.
Fenbendazole has pharmacokinetic data primarily in veterinary species. While human case reports exist, the pharmacokinetic profile in humans is less well-defined. Dosing guidance for fenbendazole in cancer patients is largely extrapolated from veterinary data and anecdotal reports, which provides a less solid foundation for clinical decision-making. This isn’t to say fenbendazole is not safe. If you look at online discussions, many patients self administer fenbendazole without issue. However, this is not something we recommend.
2. Superior Preclinical Potency
In direct comparisons across cancer cell lines, mebendazole has consistently demonstrated greater anticancer potency than fenbendazole. In the Doudican et al. (2008) melanoma screening, mebendazole achieved IC50 values 3-4x lower than fenbendazole (0.30–0.32 µM vs. 1.2–1.4 µM). Nygren et al. (2013), screening 1,600 existing drugs against colon cancer cell lines, identified mebendazole as a top candidate from among a cluster of benzimidazoles that also included fenbendazole.
3. BBB Penetration with Characterized Polymorphism
As detailed earlier, mebendazole polymorph C has published data demonstrating brain tissue penetration at therapeutic concentrations. For patients with primary brain tumors or brain metastases, which represent a significant portion of advanced cancer cases, this is not a theoretical advantage. It is a practical one that can influence treatment outcomes.
4. Clinical Observations on Recurrence Patterns
This is where we share something that we believe patients need to hear, with the caveat that these are clinical observations, rather than published research.
Our compounding pharmacy colleagues, who have worked in the repurposed drug cancer space for nearly two decades, have tracked a concerning pattern among fenbendazole users. Many patients who took fenbendazole had excellent clinical results while on the drug. However, when cancer recurred after discontinuation, it tended to be more aggressive and significantly more resistant to treatment than would typically be expected.
We want to be transparent: this is observational data, not research. But it comes from nearly 18 years of clinical observation across a large number of patients, and we take it seriously. The pattern is consistent with what we know about cancer’s ability to adapt to selective pressures. If fenbendazole exerts a different pharmacodynamic profile than mebendazole, even subtly, it could create different resistance patterns upon discontinuation.
This observation reinforces two principles we hold firmly in our practice:
First, drug cycling matters. Cancer adapts. Any single-agent approach, no matter how effective initially, creates selective pressure that favors resistant cell populations. We rotate and cycle our protocols specifically to prevent this.
Second, these are not monotherapies. No single repurposed drug should be used in isolation. The multi-pathway, multi-drug approach is not just theoretically superior, it is clinically essential for durable outcomes.
5. Regulatory and Quality Control Considerations
Mebendazole is a human-approved pharmaceutical. When obtained from a reputable compounding pharmacy that verifies polymorph C, patients can have confidence in what they are receiving.
Fenbendazole is a veterinary product. The formulations available to consumers are manufactured to veterinary standards, which differ from pharmaceutical-grade human medications. Purity, consistency, and excipient profiles may vary. Patients self-sourcing fenbendazole from pet supply stores or online vendors have no way to verify what they’re actually getting.
The Evidence Base: Cancer Types Studied
Benzimidazoles have demonstrated anticancer activity across an extensive range of cancer types in preclinical studies:
Glioblastoma/Brain cancers: Mebendazole significantly extended survival in preclinical glioblastoma models and crosses the blood-brain barrier (Bai et al., 2011; Bai et al., 2015). Combination with temozolomide (standard chemotherapy) extended survival further than temozolomide alone.
Melanoma: Mebendazole identified as a lead compound from screening 2,000 molecules against chemoresistant melanoma cell lines. Induced dose-dependent apoptosis with selectivity for cancer cells over normal melanocytes (Doudican et al., 2008).
Colorectal cancer: Both mebendazole and fenbendazole identified in drug screens against colon cancer cell lines. Fenbendazole additionally showed activity against 5-fluorouracil-resistant colorectal cancer cells, relevant for patients whose cancers have stopped responding to standard chemotherapy (Nygren et al., 2013; Park et al., 2019).
Breast cancer: Mebendazole and albendazole caused selective apoptotic cell death in breast cancer cell lines while sparing normal cells (Petersen & Baird, 2021). Mebendazole depletes ALDH+ cancer stem cells in triple-negative breast cancer.
Lung cancer: Benzimidazoles have been investigated for both non-small cell lung cancer and lung adenocarcinoma. In our own case series of five metastatic lung cancer patients, polymorph C mebendazole was part of every patient’s treatment protocol alongside ivermectin and other repurposed agents. Outcomes ranged from complete remission (in an ALK-positive NSCLC patient) to sustained disease stability over 6–16 months, including in patients in their 80s and one patient receiving no conventional treatment at all.
Pancreatic cancer: Emerging evidence supports benzimidazole activity in pancreatic cancer models, particularly when combined with metabolic interventions.
Ovarian, gastric, and osteosarcoma: Additional preclinical data across these cancer types further supports the broad-spectrum anticancer activity of the benzimidazole class.
Synergy with Ivermectin: Why We Recommend Both
Mebendazole and ivermectin target cancer through different but complementary mechanisms. The first peer-reviewed protocol for the combined use of ivermectin, mebendazole, and fenbendazole in cancer was published in 2024 (Baghli, Martinez, Marik et al., 2024), providing a formal evidence-based framework for this combination approach.
The rationale for combining them:
Different primary mechanisms: Mebendazole disrupts microtubules; ivermectin disrupts PAK1/Akt/mTOR signaling, mitochondrial function, and WNT pathways. Together, they cover more cancer hallmarks simultaneously.
Complementary CSC targeting: Ivermectin targets cancer stem cells through stemness gene downregulation (NANOG, SOX2, OCT4). Mebendazole targets CSCs through Hedgehog/GLI1 inhibition and ALDH+ depletion. Different mechanisms, same critical target.
Reduced resistance potential: Multi-drug combinations reduce the likelihood that cancer cells can develop resistance to all agents simultaneously. This is the same principle behind multi-drug chemotherapy regimens. But, applied to safer, more tolerable medications.
Published synergistic effects: The combination has shown additive or synergistic anticancer effects in published preclinical data. In our clinical practice, every patient in our metastatic lung cancer case series received both polymorph C mebendazole and ivermectin as part of their multi-drug protocol—and the outcomes in that cohort, including a complete remission and multiple cases of sustained disease stability, are consistent with the synergistic benefit the research predicts.
Mebendazole should be taken with a fatty meal to improve absorption, as it has relatively low oral bioavailability (~17–20% of the dose reaching systemic circulation). Fat-soluble drugs require dietary fat for adequate absorption. This is not optional, it meaningfully affects therapeutic drug levels.
Specific dosing, cycling schedules, and protocol details are individualized in our practice based on cancer type, stage, concurrent treatments, and patient tolerability. We strongly recommend against self-dosing based on internet protocols. The difference between a thoughtful, clinician-supervised multi-drug regimen with appropriate cycling and a self-administered single-agent protocol is the difference between informed treatment and a gamble.
Safety Profile
Mebendazole has a well-established safety record from decades of human use, including long-term high-dose regimens for echinococcosis. The WHO includes mebendazole on its List of Essential Medicines.
Safety was formally evaluated across 6,276 subjects in 39 clinical trials plus decades of post-marketing experience (Guerini et al., 2019). The most common adverse effects at standard dosing are mild gastrointestinal symptoms. At higher doses used for echinococcosis, hepatotoxicity is the primary concern requiring monitoring, but this is typically at doses significantly above those used in most cancer protocols.
Drug interactions exist and must be managed, particularly with:
Significant hepatic impairment (requires monitoring of liver function)
Known hypersensitivity to benzimidazoles
Monitoring
Patients on mebendazole as part of a cancer protocol should have regular liver function monitoring, complete blood counts, and imaging per their oncologist’s schedule. This is standard practice at Leading Edge Clinic. Our nursing team provides proactive check-ins throughout treatment to manage dosing, side effects, and protocol adherence.
What This Means for Cancer Patients
If you’ve found your way to this article because you’re researching fenbendazole for cancer, here’s what we want you to take away:
The science behind benzimidazoles as anticancer agents is real. The mechanisms are well-characterized, the preclinical data is extensive, and the emerging clinical evidence is encouraging. Naysayers call this wishful thinking, placebo effect, and quackery. But, it is proven pharmacology.
Mebendazole is the superior clinical choice within this drug class for human cancer patients. This statement is based on potency data, human pharmacokinetic characterization, polymorph-specific brain penetration research, and 18 years of clinical observations from compounding pharmacy colleagues.
No benzimidazole should be used as a monotherapy. Cancer adapts. Multi-pathway coverage – using benzimidazoles alongside ivermectin, metabolic interventions, and other repurposed agents – provides the best chance at durable outcomes.
Cycling and protocol management matter. The same adaptability that makes cancer deadly also means static, unchanging drug regimens lose effectiveness over time. We cycle our protocols specifically to stay ahead of resistance.
Clinical supervision is essential. Drug interactions, polymorph verification, dosing optimization, monitoring, and integration with conventional treatment all require experienced clinical management. Our adjunctive cancer care program provides exactly this—frequent provider visits, dedicated nursing support, and protocols built on the research of Dr. Paul Marik and our own clinical experience.
Baghli I, Martinez P, Marik PE, et al. Ivermectin, Fenbendazole and Mebendazole protocol in cancer. Published September 19, 2024. Peer-reviewed protocol for combined benzimidazole use in cancer.
Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-Oncology. 2011;13(9):974-982. doi:10.1093/neuonc/nor077
Bai RY, Staedtke V, Wanjiku T, Bhatt R, Riggins GJ. Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model. Clinical Cancer Research. 2015;21(15):3462-3470. doi:10.1158/1078-0432.CCR-14-2681
Borodovsky A, Larsen AR, Bai RY, et al. Repurposing the antihelmintic mebendazole as a Hedgehog inhibitor. Molecular Cancer Therapeutics. 2015;14(1):3-13. doi:10.1158/1535-7163.MCT-14-0755-T
Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. 2018;8:11926. doi:10.1038/s41598-018-30158-6
Guerini AE, Triggiani L, Maddalo M, et al. Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature. Cancers. 2019;11(9):1284. doi:10.3390/cancers11091284. PMC6769799. https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/
Mrkvová Z, Uldrijan S, Pombinho A, Bartůněk P, Slaninová I. Benzimidazoles downregulate Mdm2 and MdmX and activate p53 in MdmX overexpressing tumor cells. Molecules. 2019;24(11):2152. doi:10.3390/molecules24112152
Nygren P, Fryknäs M, Agerup B, Larsson R. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. Journal of Cancer Research and Clinical Oncology. 2013;139(12):2133-2140. doi:10.1007/s00432-013-1539-5
Park D, Lee JH, Yoon SP. Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells. Korean Journal of Physiology & Pharmacology. 2019;23(5):377-386. doi:10.4196/kjpp.2019.23.5.377
Petersen JSSM, Baird SK. Treatment of breast and colon cancer cell lines with anti-helmintic benzimidazoles mebendazole or albendazole results in selective apoptotic cell death. Journal of Cancer Research and Clinical Oncology. 2021;147(10):2945-2953. doi:10.1007/s00432-021-03698-0
Disclaimer: This article is for educational purposes only and should not be construed as medical advice. Cancer treatment decisions should be made in consultation with qualified oncology professionals. The information presented represents current research and clinical observations; outcomes may vary. Patients should never discontinue or modify standard cancer treatments without consulting their healthcare team.
We have treated over 3,500 Long COVID and Post-Vaccine Syndrome cases since 2022. However, still, the treatments showing the most promise in clinical practice aren’t yet in the official guidelines.
This isn’t surprising. The gap between clinical innovation and institutional approval often takes years, sometimes decades, to close. That is, if they ever close at all. There is, of course, story after story of promising curative treatments purchased by pharmaceutical companies and immediately thrown in the filing cabinet of oblivion – innovation killed and stifled to maintain cash cow products that produce no meaningful results.
Now infamous, the time a Goldman Sachs analyst asked the quiet part out loud: “Is curing patients a sustainable business model?” The analyst when on to write in her report, “…such (curative) treatments offer a very different outlook with regard to recurring revenue versus chronic therapies. While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
Long COVID and Post-Vaccine Syndrome patients can’t wait to see if someone looks favorably at the economic viability of helping them with their severe and debilitating conditions. And if that endeavor is decidedly profitable (which it most certainly will be based on the current trajectory of severely ill spike protein patients), they can ill afford to wait the additional 5+ years for clinical research and testing for expensive, patented drugs that treat symptoms.
What follows is an evidence-based discussion of a small handful of treatments we’ve used successfully in clinical practice, why they work mechanistically, what the research shows, and why most physicians haven’t adopted them yet. This is by no means an exhaustive list. But, some treatments we thought were worth highlighting for one reason or another.
This represents real-world clinical experience combined with emerging research. The kind of information you need to have informed conversations with your healthcare provider.
Understanding the Treatment Gap
Before discussing specific treatments, it’s important to understand why there’s often a delay between what helps patients and what becomes “standard of care.”
Three Primary Barriers:
1. Regulatory Framework Most of these treatments are FDA-approved for other conditions but used “off-label” for Long COVID. While legal and common in medicine, off-label use requires physician comfort with clinical decision-making beyond established protocols. We saw during the pandemic that “off-label” suddenly became a dirty word, weaponized against certain drugs demonstrating promise in treatment. More on that later.
2. Evidence Timeline Rigorous clinical trials take 3-5 years from design to publication. Long COVID emerged in 2020. We’re only now seeing results from the first wave of controlled trials. Furthermore, these trials are often on patented therapies with high side effect profiles and little clinical efficacy.
3. Risk-Benefit Calculation Physicians must weigh potential benefit against professional liability, especially for treatments lacking specific FDA approval for Long COVID. Even when clinical rationale is strong. To us, the decision is easy. Integrity trumps all risk.
The result: Patients often wait years for treatments that clinical experience suggests could help now.
Treatment #1: Low-Dose Naltrexone (LDN)
What it is: Naltrexone at standard doses (50-100mg/day) treats opioid addiction. At lower doses (1-4.5mg/day), it functions as an immunomodulator with anti-inflammatory properties.
Clinical rationale for Long COVID:
Low-dose naltrexone works through multiple mechanisms relevant to Long COVID pathophysiology:
Immune modulation: Inhibits pro-inflammatory toll-like receptor 4 (TLR4), which drives cytokine production
Cytokine reduction: Decreases inflammatory markers including IL-6, TNF-alpha, and IL-1β
Ion channel restoration: A 2025 study demonstrated LDN restored TRPM3 ion channel function in Long COVID patients’ immune cells—significant because TRPM3 dysfunction impairs cellular energy production and immune response
Mast Cell Stabilization: By reducing immune reactivity and cytokine production, it also creates a more stabile environment, preventing histamine release from mast cells.
Neuroinflammatory Reduction: Reduces microglial activation in the brain, with 60% of users reporting reduction in anxiety, fatigue, and brain fog
Current evidence:
The NIH RECOVER program selected LDN for clinical trials, with enrollment beginning summer 2026. Existing data includes:
Meta-analysis of observational studies (n=155 across 4 studies): Moderate effect size for fatigue reduction (Hedges’ g = -0.74, p<0.001)
Quality of life improvements: SF-36 scores increased from 36.5 to 52.1 (p<0.0001) over 12 weeks
TRPM3 restoration study (Frontiers in Molecular Biosciences, 2025): Demonstrated objective improvement in immune cell calcium signaling
Safety profile: Excellent across multiple studies. Most common side effects are mild and transient (vivid dreams, slight headache in first 1-2 weeks)
Contraindications: Active opioid use, liver dysfunction
Clinical experience: In our practice, approximately 50-60% of Long COVID and Post-Vaccine Syndrome patients experience significant benefit from LDN. Response is most notable for fatigue, post-exertional malaise, and brain fog.
Typical response timeline: 8-12 weeks at therapeutic dose.
Prescribing approach:
Start low (0.5-1mg) to assess tolerance
Titrate slowly: increase by 0.5mg every 3-5 days
Target dose: 3-4.5mg daily
Taken at bedtime (may initially cause vivid dreams)
Requires compounding pharmacy
Why adoption is limited: Requires off-label prescribing, compounding pharmacy access, and physician comfort with immunomodulation. Many physicians prefer to wait for RECOVER trial results before prescribing. To us, it is shocking that it has taken this long to even get studies going on this low risk, high benefit option.
Treatment #2: Low-Dose Ketamine
What it is: Ketamine is an NMDA receptor antagonist originally used for anesthesia, now FDA-approved for treatment-resistant depression via the esketamine nasal spray (Spravato). We have written more extensively about its history, its mechanisms of action, and what we’ve seen in our Long Covid and Post-Vaccine Syndrome patients here
Clinical rationale for Long COVID and Post-Vaccine Syndrome:
Ketamine addresses multiple Long COVID and PACVS mechanisms:
Neuroinflammation reduction: Downregulates inflammatory cytokines (IL-6, IL-17A, TNF-alpha) that contribute to brain fog and cognitive dysfunction
Rapid-acting antidepressant: Unlike traditional SSRIs requiring 4-6 weeks, ketamine can show effects within hours to days, and takes a fundamentally different approach from serotonin based treatments
Chronic pain modulation: Effective for neuropathic pain through NMDA receptor antagonism
Current evidence:
Active clinical trials: University of British Columbia Phase 2 trial testing ketamine for Long COVID fatigue and cognitive symptoms (NCT identifier pending, 20 participants)
Case reports: Published cases demonstrating rapid improvement in treatment-resistant depression and suicidality in Long COVID patients. These reports are focused on psychological impacts. However, there are significant physiological benefits to treatment as well
Mechanism studies: Ketamine reduces specific inflammatory markers that correlate with Long COVID symptom severity
Combination therapy: German observational study showed promising results combining ketamine with repetitive transcranial magnetic stimulation (rTMS)
Administration routes:
Low-Dose Sublingual Ketamine: Although there are other administrative routes (IV, intranasal, etc…), to achieve therapeutic dosing for Long Covid and Post-Vaccine Syndrome patients, only low doses are needed. These doses can be achieved through sublingual administrations via compounded drops, or troches.
Clinical experience: Most dramatic improvements occur in patients with:
Severe fatigue with cognitive dysfunction
Chronic neuropathic pain
Persistent brain fog unresponsive to other interventions
Anxiety and depressive related disorders
Dysautonomia symptoms
Typical protocol: Daily sublingual drops or troches at minimally tolerable dose. Dosing dependent upon tolerability is based on glutamate imbalances, which are corrected over time with sublingual low-dose ketamine. Improvements are seen over a 6 month period.
Safety considerations:
Requires medical supervision and monitoring
Potential side effects with low-dose sublingual ketamine: Dissociation, minor euphoric feeling, anxiety during infusion
Contraindications: Active substance abuse (however, this can also be a treatment for substance abuse)
Not appropriate for all patients
Why adoption is limited: Off-label prescribing of low-dose sublingual ketamine for Long Covid and Post-Vaccine Syndrome is not something many clinicians are aware, let alone comfortable with. Its benefits are well-known in some psychiatric medicine circles for treatment resistant depression, but its effects on BDNF and neuronal healing are not yet mainstream for the treatment of other conditions, such as Long Covid, that impact brain health. It is a controlled substance, which means prescribers must have DEA licenses.
Treatment #3: Dimethyl Sulfoxide (DMSO)
What it is:Dimethyl sulfoxide(DMSO) is a chemical solvent and prescription medication primarily used to treat painful bladder syndrome (interstitial cystitis). It is known for its ability to rapidly penetrate skin and membranes, acting as an anti-inflammatory and analgesic agent.
Clinical rationale for Long COVID and Post-Vaccine Syndrome:
Some argue that DMSO is the most suppressed therapeutic in modern medicine because it works too well for too many things. You’ll remember from earlier in this article what the Goldman Sachs analyst said about effective, curative treatments. When the FDA banned DMSO in 1965 (despite overwhelming safety data), thousands of patients with debilitating conditions lost access to a therapy that was giving them their lives back. The parallels to how Long COVID and Post-Vaccine Syndrome patients are being dismissed today are not coincidental.
Here’s what makes DMSO uniquely suited for spike protein disease:
The Spike-Protein Connection: Why DMSO Makes Mechanistic Sense
If persistent spike protein is driving Long COVID and Post-Vaccine Syndrome pathology—and mounting evidence suggests it is—then DMSO addresses nearly every downstream mechanism we see clinically:
1. Protein Misfolding and Amyloid Fibrin Microclotting
DMSO is a chemical chaperone. It stabilizes protein folding and, critically, dissolves amyloid aggregates.
At least 40 studies have demonstrated DMSO’s ability to solubilize amyloid fibrils and enable the body to break them down. If spike protein is creating misfolded proteins or amyloid-like microclots (the leading hypothesis for many Long COVID and PACVS symptoms), DMSO has a direct mechanism of action:
Prevents proteins from aggregating into pathologic forms
Dissolves existing amyloid deposits
Allows the body to clear these aggregates through normal elimination pathways
This isn’t theoretical, or even in vitro evidence. DMSO has successfully treated amyloidosis in humans—a condition characterized by insoluble protein aggregation causing organ damage. Same mechanism, different protein.
The microclotting angle: DMSO is also a powerful platelet deaggregator and anticoagulant:
Inhibits platelet aggregation induced by ADP, collagen, arachidonic acid, and platelet-activating factor
Blocks tissue factor (TF) expression—the key link between inflammation and clotting
Unlike aspirin or heparin, it does this without bleeding risk
If microclots are clogging your microcirculation and causing tissue hypoxia, DMSO addresses it directly while simultaneously improving blood flow to oxygen-starved tissues.
2. Autoimmunity
Spike-triggered autoimmunity is one of the most devastating Long COVID mechanisms. DMSO has decades of evidence treating autoimmune conditions that conventional medicine still can’t touch:
Lupus – reduces symptoms, often allowing steroid reduction
Multiple sclerosis – stops progression in many cases, improves symptoms
Rheumatoid arthritis – 70-80% response rate in multiple studies
Scleroderma – one of the few things that works for this “untreatable” condition
Interstitial cystitis – the only FDA-approved use for DMSO (because the evidence was impossible to suppress)
Sjögren’s syndrome – dramatically improves dry mouth/eyes in published case series
Improves microcirculation – documented in studies using radioactive isotope imaging
Treats vasospasm – successfully used for Raynaud’s syndrome, peripheral neuropathy, complex regional pain syndrome
Clinical studies show DMSO:
Eliminates symptoms in 50% of Raynaud’s patients
Treats diabetic peripheral neuropathy and prevents amputations
Resolves varicose veins (sometimes within minutes of IV administration)
Improves circulation in thrombophlebitis and peripheral artery disease
If spike-ACE2 interaction is damaging your vasculature, DMSO protects and heals blood vessels.
4. Neurological Protection and Small Fiber Neuropathy
Small fiber neuropathy is the #4 most common vaccine injury symptom. It’s also prevalent in Long COVID.
DMSO selectively blocks C-fibers and A-delta fibers—the exact nerve fibers responsible for burning pain, electrical shocks, pins-and-needles, and the agonizing dysesthesias of small fiber neuropathy.
Mechanism:
Blocks nerve conduction in small pain fibers without affecting larger motor/sensory fibers
Suppresses NMDA and AMPA receptor activity (central pain sensitization)
Blocks excessive calcium/sodium influx into pain-transmitting neurons
Does NOT create tolerance (unlike opioids—often becomes MORE effective over time)
Additionally, DMSO crosses the blood-brain barrier and:
Protects neurons from death following ischemia/hypoxia
Reduces neuroinflammation
Treats brain fog, cognitive dysfunction (reported extensively in Long COVID patients using DMSO)
Has successfully treated traumatic brain injuries, strokes, spinal cord injuries in studies the FDA ignored
5. Organ Protection and Healing
DMSO doesn’t just reduce symptoms, it heals damaged tissue. This is critical for Long COVID and Post-Vaccine Syndrome patients with organ involvement (which would be most patients):
Lungs:
Reduces pulmonary fibrosis (case reports of transplant candidates recovering)
Treats COPD, asthma exacerbations
Improves oxygenation in respiratory insufficiency
81% of patients with chronic respiratory failure improved without hospitalization in one study
Dosing: We start with topical and/or oral dosing based on specific patient needs, titrating appropriately based on response and tolerability. Some patients seek out IV administration for more aggressive treatment, though this is logistically challenging outside specialized clinics.
Expected timeline:
Acute symptoms (pain, inflammation): Often improve within hours to days
Chronic conditions: 4-7 days to start seeing benefit, 6-8 weeks for sustained improvement
DMSO often becomes MORE effective with continued use (opposite of pharmaceutical tolerance)
Contraindications and cautions:
Pregnancy/breastfeeding – inadequate safety data (though one study showed safe use for infertility)
Active skin infections – DMSO can carry surface toxins into the body; ensure skin is clean before application
Severe liver or kidney dysfunction – use with caution, monitor closely
Concurrent DMSO + PRP injections – may reduce PRP efficacy due to platelet inhibition
Allergic reactions – rare (~1 in 2000) but possible; start with low concentration to assess tolerance
Skin irritation with topical use (concentration-dependent, often resolves with continued use)
Nausea (uncommon with appropriate dosing)
Why You Haven’t Heard About This
The FDA banned DMSO research in 1965 based on a fabricated safety concern (lens opacities in dogs—which never occurred in any other species or in humans). Despite Congressional hearings, outcry from patients and physicians, and a former Secretary of Health and Human Services championing it after using DMSO to treat his wife’s terminal cancer pain, the FDA never relented.
Why? DMSO threatened too many profitable drug markets.
In 1966, over 1,000 researchers presented evidence at the Waldorf Astoria. Zero withdrew their papers despite FDA pressure. The data was overwhelming.
Sixty years later, patients are still suffering from conditions DMSO could treat—because the FDA decided your access to effective medicine was less important than protecting pharmaceutical profits.
For Long COVID patients failed by the medical establishment, DMSO represents what medicine should have been: safe, effective, accessible, and focused on healing rather than management.
Bottom line on DMSO for Long COVID:
If persistent spike protein is causing:
Protein misfolding → DMSO refolds and stabilizes proteins
Amyloid microclots → DMSO dissolves aggregates and prevents platelet aggregation
Organ damage → DMSO protects lungs, gut, heart, kidneys
The mechanism isn’t speculative. The evidence isn’t anecdotal. This is decades of suppressed research finally reaching patients who need it.
Treatment #4: Microcurrent Therapy
What it is: Microcurrent therapy delivers sub-sensory electrical currents in the microampere range — currents so small they mimic the body’s own bioelectrical signals. We commonly have recommended the Arc Microtech device. The Arc device was engineered by Ian Thirkell, a retired English detective who spent years studying the bioelectricity research of Dr. Robert O. Becker after his wife handed him three of Becker’s books and told him to go learn something useful.
The scientific foundation is worth understanding. Becker was an orthopedic surgeon and researcher at the VA Hospital in Syracuse, New York, who spent decades studying how the body uses electrical signals to heal. He discovered that injury generates a measurable shift in voltage at the wound site — a “current of injury” — that initiates the healing process. He demonstrated that applying tiny electrical currents could stimulate partial limb regeneration in rats (published in Nature, 1972) and developed techniques using electrically generated silver ions to fight antibiotic-resistant infections and promote tissue regeneration in human patients. His core insight, detailed in his landmark book The Body Electric (1985): the body operates on a bioelectrical control system that can be supported and restored through the careful application of currents matching the body’s own frequencies. The ARC device is built directly on this principle.
Clinical rationale for Long COVID and Post-Vaccine Syndrome:
ATP production enhancement: The landmark 1982 study by Cheng et al. demonstrated that microcurrent stimulation in the 100-500 microampere range increased ATP production by up to 500% in treated tissue, while increasing amino acid transport by 30-40% and enhancing protein synthesis. When current was increased into the milliampere range used by TENS units, ATP production actually decreased. This distinction matters enormously: Long COVID and Post-Vaccine Syndrome patients have documented mitochondrial dysfunction. A 2025 study in Annals of Medicine confirmed that immune cells from Long COVID patients exhibit aberrant ATP synthase function, resulting in diminished cellular energy availability. The spike protein — whether from viral reservoirs or circulating post-vaccination — impairs oxidative phosphorylation, the process responsible for 90% of cellular energy production. Fatigue, post-exertional malaise, brain fog, exercise intolerance — these are manifestations of cells that cannot produce adequate energy (although there is greater detail as to what is happening here, some of this is detailed in our prior article on cell danger response). Microcurrent directly targets this deficit.
Inflammation reduction: Microcurrent reduces inflammatory markers and promotes resolution of swelling through enhanced circulation and lymphatic drainage — relevant to the chronic systemic inflammation driving Long COVID and Post-Vaccine Syndrome symptoms
Tissue repair and cellular regeneration: Building on Becker’s work, microcurrent stimulates fibroblast activity, enhances collagen synthesis, and promotes angiogenesis. For patients with endothelial damage and microclotting from spike protein, these repair mechanisms are critical. We have seen patients in heart failure restore their ejection fraction back to well over the CHF baseline.
Autonomic and neurological support: Clinical observations from our practice and colleagues in the UK suggest meaningful benefit for patients with autonomic dysfunction, anxiety, depression, and PTSD — conditions that frequently accompany Long COVID and Post-Vaccine Syndrome
One framing we find useful: supplements that support mitochondrial function — CoQ10, B vitamins, magnesium — are static interventions for what is fundamentally a dynamic process. They provide raw materials. Microcurrent is a dynamic intervention: it actively stimulates the cellular machinery to do its job. The two approaches are complementary, not competing.
Current evidence:
Cheng et al. (1982): Foundational study demonstrating 500% ATP increase at therapeutic microcurrent levels, with concurrent increases in amino acid transport and protein synthesis Becker’s published work (1961-1998): Decades of peer-reviewed research on bioelectrical control of regeneration, published in Nature, Science, and other major journals Modern reviews: A 2025 narrative review confirmed microcurrent’s role in enhancing ATP synthesis, improving mitochondrial efficiency, and activating tissue repair mechanisms No randomized controlled trials specific to microcurrent for Long COVID exist, and they may never — putting it in the same category as most treatments on this list when they were first adopted clinically.
Clinical experience: In our practice, over 500 patients have used the ARC device. It has been a reliable and safe recommended interventions for a few years now.
Most consistent improvements:
Fatigue — the most reliably reported benefit, typically noticeable after approximately six weeks of consistent use Pain and inflammation — reduced swelling and bruising, notably effective for patients on anticoagulation therapy Cardiac function — we have observed cases of improved cardiac ejection fraction with sustained use, corroborated by colleagues in the UK Brain fog and cognitive function — improvements likely related to enhanced cellular energy production and reduced neuroinflammation Anxiety and trauma-related symptoms — consistent with observations from military psychiatrists using microcurrent for treatment-resistant PTSD
Benefit is cumulative. More consistent use produces greater results.
Typical protocol:
Program 1 (100% anti-inflammatory): At least one 3-hour cycle daily for two months Program 2 (50% anti-inflammatory, 50% cellular repair): At least one 3-hour cycle daily for two weeks Program 3 (25% anti-inflammatory, 75% cellular repair): At least one 3-hour cycle daily for two weeks Then rotate: One week each of Programs 1, 2, and 3, repeating continuously
Worn on the arm or leg (most patients prefer above the ankle). The strap should be fitted but not tight — two fingers should fit between strap and skin. Tightness inhibits circulation and reduces benefit.
Response timeline: Most patients notice benefit after approximately six weeks. Some report improvement within days, particularly for pain and inflammation. However, some patients even report improved energy in just days.
Safety considerations:
Excellent safety profile — these are sub-sensory currents operating at the same magnitude as the body’s own cellular electrical signaling Approximately 5% of patients experience initial sensitivity (nausea, dizziness), managed by starting with very short sessions and gradually increasing No significant adverse effects observed in our patient population Safe for use alongside other treatments, including anticoagulation Contraindications: Active implanted electrical devices (pacemakers, defibrillators)
Why adoption is limited: Microcurrent therapy sits entirely outside the pharmaceutical paradigm. There is no drug to prescribe, no procedure to bill for, and no pharmaceutical company funding trials. Becker himself faced significant institutional resistance throughout his career — his research challenged the chemical-mechanistic model of biology, and his opposition to electromagnetic pollution put him at odds with powerful interests. The ARC Microtech is a small, family-owned UK company without resources for large-scale clinical trials. And the concept that a wearable device delivering imperceptible electrical currents can meaningfully impact chronic illness strikes most conventionally trained physicians as implausible, despite decades of published research supporting the underlying science.
Our perspective: Microcurrent therapy, and specifically the ARC device, is one of the most underappreciated tools in our clinical arsenal. It is non-invasive, has an excellent safety profile, produces cumulative benefit, and directly addresses what may be the single most important pathological mechanism in Long COVID and Post-Vaccine Syndrome: mitochondrial energy failure. For a condition where the body has lost its ability to produce adequate energy, providing it with the bioelectrical signal to restore that production isn’t alternative quackery — it’s the application of proven biophysics.
Conflicts of Interest: We do offer a discount code for the ARC Microtech device. Using code USARCLEC at checkout on the ARC website provides a $20 discount to ordering customers. ARC also provides us with $20. However, we have never stashed this money away in a bank account. We have historically used this money to re-invest into devices for patients who can not afford to invest in this special device.
Treatment #5: Ivermectin
The controversial treatment that requires honest discussion.
Ivermectin became one of the most politicized medications in modern history. That makes it difficult to have rational, evidence-based conversations about its potential role in Long COVID and Post-Vaccine Syndrome.
Here’s what we actually know:
What it is: An antiparasitic medication on the WHO’s List of Essential Medicines, with an excellent 40-year safety record from billions of doses administered globally.
Theoretical mechanisms for Long COVID and Post-Vaccine Syndrome:
1. Spike Protein and ACE2 Receptor Interaction: This is perhaps the most relevant mechanism for Long COVID and Post-Vaccine Syndrome. Multiple molecular docking studies have demonstrated that ivermectin binds to:
The spike protein receptor-binding domain (RBD): Where the spike protein attaches to ACE2 receptors
The spike-ACE2 complex interface: Specifically between leucine 91 of the spike protein and histidine 378 of the ACE2 receptor
The N-terminal domain (NTD): Which controls initial viral attachment to cell membranes
Binding energy studies show strong affinity (-18 kcal/mol), suggesting ivermectin may physically interfere with spike protein attachment to ACE2 receptors.
Why this matters for Long COVID and Post-Vaccine Syndrome: If persistent spike protein (either from viral reservoirs or circulating spike) is driving symptoms—a leading hypothesis in Long COVID and Post-Vaccine Syndrome pathophysiology—ivermectin’s ability to bind both spike protein and ACE2 receptors could theoretically:
Reduce spike-mediated inflammation and endothelial damage
2. Additional antiviral mechanisms:
TMPRSS2 binding: Ivermectin binds to TMPRSS2, a protease that activates spike protein for cell entry
Viral replication inhibition: Demonstrated in vitro inhibition of SARS-CoV-2 replication
Multiple viral protein targets: Binds to main protease (Mpro), RNA-dependent RNA polymerase (RdRp), and nucleocapsid proteins
3. Anti-inflammatory effects:
Inhibits nuclear import of inflammatory transcription factors
Reduces cytokine production (IL-6, TNF-alpha, IL-1β)
Modulates immune response through multiple pathways
Important concentration caveat: While docking studies predict strong binding, debate exists about whether therapeutically achievable concentrations in humans are sufficient for these effects. One 2024 study suggested effective spike binding required concentrations 100-1000x the approved dosage in their assay system, though other studies and clinical observations suggest benefit at standard doses. Our clinical observations suggest extremely safe dosing ranges are effective in about 70% of patients.
The discrepancy may relate to:
Differences between in vitro assays and in vivo conditions
Tissue concentration versus serum concentration
Individual pharmacokinetic variation
Duration of exposure in chronic dosing versus single-dose studies
The evidence landscape:
The data on ivermectin for acute COVID-19 was mixed, politicized, and contentious. For Long COVID specifically:
No published randomized controlled trials
Mechanistic rationale exists
Clinical experience varies among practitioners. Our experience suggests a 70% positive clinical response rate
Clinical experience: In our practice, we’ve observed a subset of patients—approximately 70%—who report improvement when ivermectin is included as part of a comprehensive treatment protocol.
Important caveats:
Not a monotherapy; used as part of multi-modal approach
Standard anti-parasitic dosing (not megadoses)
Drug interactions exist
Why adoption is limited: The political controversy surrounding ivermectin creates significant professional risk for physicians who prescribe it, even for legitimate clinical indications. Many state medical boards have issued warnings, and physicians face potential peer censure. Dr. Kory had his board certifications revoked for promoting its use in acutely ill COVID patients, even in spite of positive clinical responses.
Our perspective: With Dr. Kory having testified before the Senate about COVID treatments and faced professional consequences for advocating treatments outside the mainstream, we believe in the efficacy of ivermectin based on excellent safety profile, low cost, and high clinical response rates.
The question for any treatment should be: What does the evidence show, what is the safety profile, and what is the clinical experience?
For ivermectin in Long COVID and Post-Vaccine Syndrome: Mainsteam evidence is limited, the safety profile is excellent, and our clinical experience is positive.
Whether to try it should be an informed decision between patient and physician, weighing potential benefits against minimal risks.
Treatment #6: Anticoagulation Therapy
What it is: Blood-thinning medications ranging from aspirin to low-dose anticoagulants.
Clinical rationale:
Growing evidence suggests microclots may play a role in Long COVID:
Microclot hypothesis: Persistent microclotting causing tissue hypoxia and symptoms
Proven benefit in acute COVID: Anticoagulation improves outcomes in hospitalized patients
Current evidence: Mechanistically compelling. Clinical trials underway but results pending.
Clinical experience: Some patients show improvement with aspirin or low-dose anticoagulation. Requires careful patient selection and monitoring.
Safety considerations: Bleeding risk requires careful assessment. Not appropriate for all patients.
Why adoption is limited: Balancing benefit versus bleeding risk requires individualized assessment. Physicians appropriately cautious about anticoagulating without clear indication.
The Gap Between Evidence and Practice
Every treatment discussed here shares common characteristics:
Mechanistic rationale based on Long COVID and PACVS pathophysiology
Existing clinical experience supporting use
Acceptable safety profiles when used appropriately
Real clinical results within our treatment of over 3,500 Long Covid and Post-Vaccine Syndrome patients
Yet most physicians haven’t adopted them. Why?
The Institutional Reality:
Evidence requirements: Institutions typically require randomized controlled trials before treatment adoption. These trials take years.
Liability concerns: Off-label prescribing, while legal, increases perceived malpractice risk.
Guideline absence: Without official clinical guidelines, physicians lack institutional backing for treatment decisions.
Professional pressure: Medical boards, peer review, and institutional policies create incentives to wait for official recommendations.
This creates a gap: Patients suffering now while waiting for evidence that may take years to generate.
What You Should Know
These Treatments Aren’t Magic Bullets
Long COVID and Post-Vaccine Syndrome are heterogeneous and complex. Treatment response varies significantly between patients.
The ideal scenario would be completed randomized controlled trials for each treatment.
What we actually have:
Mechanistic understanding (how they should work)
Clinical experience (what we’ve observed)
Emerging trial data (what’s being formally tested)
Urgent patient need (can’t wait years for perfect evidence)
The challenge: Balancing the desire for perfect evidence with the reality of patients suffering now.
This Requires Specialized Care
Optimal Long COVID and Post-Vaccine Syndrome treatment requires a clinician who:
Understands complex post-viral illness
Can navigate off-label prescribing appropriately
Will monitor carefully for adverse effects
Knows when to adjust or discontinue treatment
Can integrate multiple therapeutic modalities
Not all physicians have this expertise or comfort level.
Clinical Outcomes
In our practice of 3,500+ Long COVID patients:
80-85% achieve significant functional improvement
This means:
Return to work (often with modifications initially)
Ability to exercise (frequently at reduced level initially)
Brain fog resolved or significantly improved
Fatigue reduced to manageable levels
Quality of life substantially better
Realistic timeline: 9-18 months on average
Long COVID and Post-Vaccine Sydnrome are chronic conditions requiring sustained treatment. Promises of rapid recovery are unrealistic for most patients.
Finding Appropriate Care
If you’re considering these treatments:
1. Informed discussion with your current physician Share this information. Ask if they’re willing to consider these approaches.
2. Seek Long COVID expertise Find physicians with specific experience treating post-viral illness.
3. Consider telemedicine options Some Long COVID and PACVS specialists work across state lines via telemedicine.
4. Join support communities Other patients can recommend physicians with Long COVID expertise.
5. Be your own advocate Come prepared with questions. Understand the rationale. Participate actively in treatment decisions.
The Bottom Line
Long COVID and PACVS treatment requires:
Integration of emerging research
Clinical judgment based on experience
Willingness to use approved medications for new indications
Patient-centered approach to risk-benefit analysis
Honest acknowledgment of uncertainty
Not all physicians are equipped or willing to practice this way. The traditional model of “wait for definitive evidence” serves patients poorly when that evidence is years away.
At our practice, we integrate the best available evidence with clinical experience from over 3,500 cases. We’re transparent about what we know, what we don’t know, and what we’ve observed.
This represents clinical medicine as it should be practiced: Thoughtful, evidence-informed, patient-centered, and unafraid of reasonable uncertainty.
If you’re a Long COVID or Post-Vaccine Syndrome patient seeking care that integrates clinical experience with emerging research, we treat complex post-viral cases at Leading Edge Clinic. Our approach is based on 3,500+ patient encounters, current medical literature, and individualized treatment planning.
Baldwin K, Wanson A, Gilecki L-A, Dalton C, Peters E, Halpape K. Intranasal ketamine as a treatment for psychiatric complications of long COVID: a case report. Mental Health Clinician. 2023;13(5):239-243. doi:10.9740/mhc.2023.10.239. PMC10732124. https://pmc.ncbi.nlm.nih.gov/articles/PMC10732124/
Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19. ClinicalTrials.gov Identifier: NCT06821087. University of British Columbia. https://clinicaltrials.gov/study/NCT06821087
Rolle C, Scheib M, Frank A, Russ I. Treatment of Chronic Fatigue Syndrome (CFS) in Post-SARS-CoV-2 Infection through combined outpatient Neuromodulation Therapy with Repetitive Transcranial Magnetic Stimulation (rTMS) and Ketamine IV Therapy — A Case Series. International Clinical Medical Case Reports Journal. https://ketaminplus.com/en/medical-studies
Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacological Reviews. 2018;70(3):621-660. doi:10.1124/pr.117.015198.
Treatment #3: DMSO
Amyloid fibril dissolution / chemical chaperone:
Dzwolak W, Loksztejn A, Smirnovas V. Noncooperative dimethyl sulfoxide-induced dissection of insulin fibrils: toward soluble building blocks of amyloid. Biochemistry. 2009;48(26):6272-6284. https://pubmed.ncbi.nlm.nih.gov/19385641/
Kardos J, Yamamoto K, Hasegawa K, et al. Dissolution of beta2-microglobulin amyloid fibrils by dimethylsulfoxide. Journal of Biological Chemistry. 2003;278(24):21222-21227. https://pubmed.ncbi.nlm.nih.gov/12944383/
Hoshino M, Katou H, Hagihara Y, et al. Dimethylsulfoxide-quenched hydrogen/deuterium exchange method to study amyloid fibril structure. Biochimica et Biophysica Acta (BBA) – Biomembranes. 2007;1768(8):1886-1899. https://www.sciencedirect.com/science/article/pii/S0005273607000703
Iwai A, Yoshida T, Saito T, et al. Studies on biological actions of dimethyl sulfoxide in familial amyloidosis. Annals of the New York Academy of Sciences. 1983;411:52-64. https://pubmed.ncbi.nlm.nih.gov/6576722/
Amemori S, Iwakiri R, Ootani H, et al. Oral dimethyl sulfoxide for systemic amyloid A amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review. Journal of Gastroenterology. 2006;41:444-449. https://link.springer.com/article/10.1007/s00535-006-1792-3
Asmis LM, Bazargan A, Pellegrin M, et al. DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents? Biochemical and Biophysical Research Communications. 2010;391(4):1629-1633. https://pubmed.ncbi.nlm.nih.gov/20035720/
Saeed SA, Rasheed H, Ali TH, et al. Effects of dimethyl sulphoxide on aggregation of human blood platelets. Experimental and Molecular Pathology. 1987;46(2):159-169. https://pubmed.ncbi.nlm.nih.gov/2880990/
Rosenblum WI. Dimethyl sulfoxide effects on platelet aggregation and vascular reactivity in pial microcirculation. Annals of the New York Academy of Sciences. 1983;411:110-119. https://pubmed.ncbi.nlm.nih.gov/6410963/
Rosenblum WI. Dimethyl sulfoxide (DMSO) and glycerol, hydroxyl radical scavengers, impair platelet aggregation within and eliminate the accompanying vasodilation of, injured mouse pial arterioles. Stroke. 1982;13(1):35-39. https://www.ahajournals.org/doi/10.1161/01.str.13.1.35
Cheng N, Van Hoof H, Bockx E, et al. The effects of electric currents on ATP generation, protein synthesis, and membrane transport in rat skin. Clinical Orthopaedics and Related Research. 1982;(171):264-272.
Becker RO. Stimulation of partial limb regeneration in rats. Nature. 1972;235(5333):109-111.
Becker RO, Spadaro JA. Electrical stimulation of partial limb regeneration in mammals. Bulletin of the New York Academy of Medicine. 1972;48(4):627-641.
Becker RO, Chapin S, Sherry R. Regeneration of the ventricular myocardium in amphibians. Nature. 1974;248(444):145-147.
Becker RO, Selden G. The Body Electric: Electromagnetism and the Foundation of Life. William Morrow & Company; 1985.
Becker RO. Iontopheretic system for stimulation of tissue healing and regeneration. US Patent 5814094A. 1998.
Jonik S, Rothka AJ, Cherin N. Investigating the therapeutic efficacy of microcurrent therapy: a narrative review. Journal of Rehabilitation Medicine. 2025. PMC12357078. https://pmc.ncbi.nlm.nih.gov/articles/PMC12357078/
Piras A, Trofè A, Piperi I, et al. Physiological effects of microcurrent and its application for maximising acute responses and chronic adaptations to exercise. European Journal of Applied Physiology. 2022. https://link.springer.com/article/10.1007/s00421-022-05097-w
Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo. 2020;34(5):3023-3026. PMC7652439. https://pmc.ncbi.nlm.nih.gov/articles/PMC7652439/
Eweas AF, Alhossary AA, Abdel-Moneim AS. Molecular docking reveals ivermectin and remdesivir as potential repurposed drugs against SARS-CoV-2. Frontiers in Microbiology. 2021;11:592908. doi:10.3389/fmicb.2020.592908.
Ahmad S, Waheed Y, Abro A, Abbasi SW, Ismail S. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2. Structural Chemistry. 2021;32:1441-1452.
[2024 NTD binding study — Ivermectin binds spike N-terminal domain across variants including KP.3. Viruses (MDPI). 2024.]
Treatment #6: Anticoagulation Therapy
Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochemical Journal. 2022;479(4):537-559. doi:10.1042/BCJ20220016. https://portlandpress.com/biochemj/article/479/4/537/230829/
Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovascular Diabetology. 2022;21(1):148. doi:10.1186/s12933-022-01579-5. https://link.springer.com/article/10.1186/s12933-022-01579-5
Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovascular Diabetology. 2021;20:172. doi:10.1186/s12933-021-01359-7.
Grobbelaar LM, Venter C, Vlok M, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Bioscience Reports. 2021;41(8):BSR20210611. doi:10.1042/BSR20210611.
Kruger A, Vlok M, Turner S, et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovascular Diabetology. 2022;21(1):190. doi:10.1186/s12933-022-01623-4. PMC9491257. https://pmc.ncbi.nlm.nih.gov/articles/PMC9491257/
Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. European Heart Journal. 2020;41(32):3038-3044. doi:10.1093/eurheartj/ehaa623.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. All treatments discussed require physician supervision. Consult a qualified healthcare provider before starting any new treatment. Individual results vary. Treatment decisions should be made in consultation with your physician based on your specific medical history and circumstances.
